Immunotherapy Combo Shows Promise for Hodgkin Lymphoma

A phase 2 study evaluates the safety and efficacy of brentuximab vedotin and nivolumab plus chemotherapy in patients with early-stage classical Hodgkin lymphoma.
Medscape Medical News

source https://www.medscape.com/viewarticle/immunotherapy-combo-shows-promise-hodgkin-lymphoma-2026a1000c8x?src=rss